| Orginal Article |
|
|
|
|
| Novel Coronavirus Control and the Important Contribution of Interferon α1b |
CHENG Yong-qing( ),LIU Jin-yi,LIN Fu-Yu,TONG Mei |
| Beijing Tri-Prime Gene Pharmaceutical Co., Ltd.,Beijing 102600,China |
|
|
|
Abstract Interferon has broad-spectrum antiviral, immunomodulatory and antitumor effects. Recombinant human interferon α1b is the first class I genetic engineering new drug with independent intellectual property rights in China. After years of research, a variety of dosage forms such as recombinant human interferon α1b injections and sprays for children and adults have been developed. A series of pharmacological, toxicological, pharmacokinetic and clinical studies on interferon α1b for the treatment of pneumonia such as coronavirus have been completed, becoming clinical consensus and guidance documents. According to these results, interferon α aerosol inhalation was recommended as the first anti-viral treatment of novel coronavirus caused pneumonia in multi-version of "National diagnosis and treatment of novel coronavirus caused pneumonia" released by National Health Commission of the People's Republic of China, and achieved good medical effects. Recombinant human interferon α1b spray, as a drug that can prevent viral infections, is widely used in the biological protection of high-exposure populations such as medical personnel, which plays an important role in the prevention and control of the epidemic, and will make contributions to national health and biosafety.
|
|
Received: 24 February 2020
Published: 27 March 2020
|
|
|
|
Corresponding Authors:
Yong-qing CHENG
E-mail: ycheng@triprime.com
|
|
|
| [1] |
Isaacs A, Lindenmann J . Virus interference. I. The interferon. Proc R Soc Lond Ser B Biol Sci, 1957,147(927):258-267.
|
|
|
| [2] |
Sidney P, Christopher D K, Mark R W , et al. Interferons, interferon-like cytokines, and their receptors. Immunol Rev, 2004,202:8-32.
|
|
|
| [3] |
Schoggins J W, Rice C M . Interferon-stimulated genes and their antiviral effector functions. Curr opin virol, 2011,1(6):519-525.
|
|
|
| [4] |
Mehta H V, Jones P H, Weiss J P , et al. IFN-α and lipopolysaccharide upregulate APOBEC3 mRNA through different signaling pathways. J Immunol, 2012,189(8):4088-4103.
|
|
|
| [5] |
David M . Signal transduction by type I interferons. Biotechniques, 2002,Suppl(2):58-65.
|
|
|
| [6] |
Lekmine F, Uddin S, Sassano A , et al. Activation of the p70 S6 kinase and phosphorylation of the 4E-BP1 repressor of mRNA translation by type I interferons. J Biol Chem, 2003,278(30):27772-27780.
|
|
|
| [7] |
Uematsu S, Akira S . Toll-like receptors and type I interferons. J Biol Chem, 2007,282(21):15319-15323.
|
|
|
| [8] |
侯云德, 张智清, 杨新科 , 等. 人白细胞干扰素基因的克隆化及其在大肠杆菌中的表达. 中国医学科学院学报, 1982,6:4-12.
|
|
|
| [8] |
Hou Y D, Zhang Z Q, Yang X K , et al. Cloning of human leukocyte interferon gene and its expression in E. coli. Journal of the Chinese Academy of Medical Sciences, 1982,6:4-12.
|
|
|
| [9] |
北京三元基因工程有限公司. 一种稳定的重组人干扰素α1b水溶液:中国,CN200410069390.4.[2006-1-25]. http://pss-system.cnipa.gov.cn/sipopublicsearch.
|
|
|
| [9] |
Beijing Tri-Prime Gene Pharmaceutical Co., Ltd.. A stable recombinant human interferon α1b aqueous solution: China, CN200410069390.4..[2006-1-25]. http://pss-system.cnipa.gov.cn/sipopublicsearch.
|
|
|
| [10] |
中华医学会临床药学分会, 雾化吸入疗法合理用药专家共识. 医药导报, 2019,38(2):135-146.
|
|
|
| [10] |
Clinical Pharmacy Branch of Chinese Medical Association. Expert consensus on rational use of nebulized inhalation therapy. Medical Herald, 2019,38(2):135-146.
|
|
|
| [11] |
王雪, 陈韡亚, 杨飞飞 , 等. 重组人干扰素α1b注射液的雾化可吸入性研究. 国际药学研究杂志, 2019,46(6):456-460.
|
|
|
| [11] |
Wang X, Chen Y Y, Yang F F , et al. Studies on nebulization respirability of recombinant human interferon α 1b. International Journal of Pharmaceutical Research, 2019,46(6):456-460.
|
|
|
| [12] |
刘鉴峰, 刘金剑, 褚丽萍 , 等. 雾化吸入干扰素α1b在兔体内的分布及代谢途径. 医药导报, 2013,32(1):1-5.
|
|
|
| [12] |
Liu J F, Liu J J, Chu L P , et al. Distribution and metabolic pathways of aerosolized interferon α1b in rabbits. Medical Herald, 2013,32(1):1-5.
|
|
|
| [13] |
孙薇, 乔逸, 郭丽 , 等. 小儿注射重组人干扰素α1b 治疗病毒性肺炎的耐受性及安全性. 中国新药杂志, 2011,20(23):2340-2344.
|
|
|
| [13] |
Sun W, Qiao Y, Guo L , et al. Tolerability and safety of pediatric injection of recombinant human interferon α1b in the treatment of viral pneumonia. Chinese Journal of New Drugs, 2011,20(23):2340-2344.
|
|
|
| [14] |
尚云晓, 黄英, 刘恩梅 , 等. 雾化吸入重组人干扰素α1b治疗小儿急性毛细支气管炎多中心研究. 中国实用儿科杂志, 2014,29(11):840-844.
|
|
|
| [14] |
Shang Y X, Huang Y, Liu E M , et al. Multicenter study of nebulized inhaled recombinant human interferon α1b in the treatment of children with acute bronchitis. Chinese Journal of Practical Pediatrics, 2014,29(11):840-844.
|
|
|
| [15] |
Jiang R M, Han B, Song M H , et al. Randomized, double-blind, placebo-controlled, multicenter clinical study of recombinant human interferon α1b aerosol inhalation for noninfluenza viral pneumonia. Inflammation, 2020, accepsubmitted.
|
|
|
| [16] |
Zhu N, Zhang D, Wang W , et al. A novel coronavirus from patients with pneumonia in China. N Engl J Med. 2020 Jan 24. doi: 10.1056/NEJMoa2001017.
doi: 10.1056/NEJMoa2001017
|
|
|
| [17] |
Zhou P, Yang X L, Wang X G , et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020 Feb 3. doi: 10.1038/s41586-020-2012-7.
doi: 10.1038/s41586-020-2012-7
|
|
|
| [18] |
Lam T TY, Shum M HH, Zhu H C , et al. Identification of 2019-nCoV related coronaviruses in Malayan pangolins in southern China. BioRxiv, 2020. doi. org/10.1101/2020.02.13.945985.
doi: org/10.1101/2020.02.13.945985
|
|
|
| [19] |
Wu A, Peng Y, Huang B , et al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe, 2020, doi: 10.1016/j.chom.2020.02.001.
doi: 10.1016/j.chom.2020.02.001
|
|
|
| [20] |
Yang Y, Lu Q B, Liu M J , et al. Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China. medRxiv, 2020, https://doi.org/10.1101/2020.02.10.20021675.
|
|
|
| [21] |
Kindler E, Thiel V . To sense or not to sense viral RNA--essentials of coronavirus innate immune evasion. Curr Opin Microbio, 2014,20:69-75.
|
|
|
| [22] |
Zhao L, Jha B K, Wu A , et al. Antagonism of the interferon-induced OAS-RNase L pathway by murine coronavirus ns2 protein is required for virus replication and liver pathology. Cell Host Microbe, 2012,11(6):607-616.
|
|
|
| [23] |
Hu Y, Li W, Gao T , et al. The severe acute respiratory syndrome coronavirus nucleocapsid inhibits type I interferon production by interfering with TRIM25-mediated RIG-I ubiquitination. J Virol, 2017,91(8):e02143-16.
|
|
|
| [24] |
Tumpey T M, Basler C F, Aguilar P V , et al. Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science, 2005,310(5745):77-80.
|
|
|
| [25] |
Roberts A, Deming D, Paddock C D , et al. A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice. PLoS Pathog, 2007,3(1):e5.
|
|
|
| [26] |
孙莉, 刘殿波, 杨宇东 , 等. 人类冠状病毒调节宿主抗病毒天然免疫分子机制. 生物化学与生物物理进展, 2010,37(3):239-244.
|
|
|
| [26] |
Sun L, Liu D B, Yang Y D , et al. Molecular mechanisms of human coronavirus regulating host-antiviral natural immunity. Advances in Biochemistry and Biophysics, 2010,37(3):239-244.
|
|
|
| [27] |
段招军, 张丽兰, 谢志萍 , 等. 不同型别重组人干扰素在细胞培养上抗SARS病毒的研究. 中华实验和临床病毒学杂志, 2003,17(3):205-208.
|
|
|
| [27] |
Duan Z J, Zhang L L, Xie Z P , et al. Study on anti-SARS effects in cell culture of different types of recombinant human interferons. Chinese Journal of Experimental and Clinical Virology, 2003,17(3):205-208.
|
|
|
| [28] |
Barnard D L, Day C W, Bailey K , et al. Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice. Antivir Chem Chemoth, 2006,17(5):275-284.
|
|
|
| [29] |
Falzarano D, Wit E, Rasmussen A L , et al. Treatment with interferon-alpha 2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med, 2013,19(10):1313-1317.
|
|
|
| [30] |
郭利民, 刘景院, 蔡皓东 , 等. SARS的临床特点与治疗研究. 中国临床医生, 2003,31(1):17-20.
|
|
|
| [30] |
Guo L M, Liu J Y, Cai H D , et al. Clinical characteristics and treatment of SARS. Chinese Clinician, 2003,31(1):17-20.
|
|
|
| [31] |
付琦, 李志刚, 马烈 , 等. SARS抗病毒治疗的药物选择探讨. 解放军药学学报, 2003,19(6):410-413.
|
|
|
| [31] |
Fu Q, Li Z G, Ma L , et al. Discussion on drug selection for SARS antiviral therapy. Pharmacy Journal of the PLA, 2003,19(6):410-413.
|
|
|
| [32] |
付琦, 李杏红, 李志刚 . 抗病毒药物治疗严重急性呼吸道综合征时机的探讨. 中国药物与临床, 2003,3(5):389-391.
|
|
|
| [32] |
Fu Q, Li X H, Li Z G . Discussion on the timing of antiviral drugs for severe acute respiratory syndrome. Chinese Medicine and Clinic, 2003,3(5):389-391.
|
|
|
| [33] |
刘冬生, 欧阳菊香, 邹敏超 , 等. 常用抗病毒药物对SARS疗效的多因素分析. 中华医院感染学杂志, 2009,19(4):434-436.
|
|
|
| [33] |
Liu D S, Ouyang J X, Zou M C , et al. Multivariate analysis of the efficacy of commonly used antiviral drugs on SARS. Chinese Journal of Nosocomiology, 2009,19(4):434-436.
|
|
|
| [34] |
申昆玲, 张国成, 尚云晓 , 等. 重组人干扰素-α1b在儿科的临床应用专家共识. 中华实用儿科临床杂志, 2015,30(16):1214-1219.
|
|
|
| [34] |
Shen K L, Zhang G C, Shang Y X , et al. Expert consensus on clinical application of recombinant human interferon-α1b in pediatrics. Chinese Journal of Practical Pediatrics, 2015,30(16):1214-1219.
|
|
|
| [35] |
申昆玲 . 儿童雾化中心规范化管理指南(第二版). 人民卫生出版社, 2016: 22.
|
|
|
| [35] |
Shen K L. Guidelines for standardized management of children’s atomization centers, 2nd ed. People's Medical Publishing House, 2016: 22.
|
|
|
| [36] |
申昆玲, 尚云晓, 张国成 , 等. α干扰素在儿科临床合理应用专家共识. 中华实用儿科临床杂志, 2018,33(17):1301-1308.
|
|
|
| [36] |
Shen K L, Shang Y X, Zhang G C , et al. Expert consensus on rational application of interferon alpha in pediatrics. Chinese Journal of Practical Pediatrics, 2018,33(17):1301-1308.
|
|
|
| [37] |
国家卫生计生委儿童用药专家委员会,中华医学会儿科学分会呼吸学组,中国医师协会儿科医师分会儿童呼吸专业委员会, 等. 儿童喘息性疾病合理用药指南. 中华实用儿科临床杂志, 2018,33(19):1460-1472.
|
|
|
| [37] |
National Committee of Health and Family Planning, Committee on Child Medication, Respiratory Group of Pediatrics Branch of Chinese Medical Association, Child Respiratory Professional Committee of Pediatrician Branch of Chinese Medical Association, et al. Guidelines for the rational use of children’s asthmatic diseases. Chinese Journal of Practical Pediatrics, 2018,33(19):1460-1472.
|
|
|
| [38] |
中华医学会儿科学分会感染学组,国家感染性疾病医疗质量控制中心. 疱疹性咽峡炎诊断及治疗专家共识(2019年版). 中华儿科杂志, 2019,57(3):177-180.
|
|
|
| [38] |
Department of Infectious Diseases, Pediatrics Branch of Chinese Medical Association, National Center for Medical Quality Control of Infectious Diseases. Expert consensus on diagnosis and treatment of herpes pharyngitis (2019 Edition). Chinese Journal of Pediatrics, 2019,57(3):177-180.
|
|
|
| [39] |
申昆玲, 王天有 . 临床路径释义-小儿内科分册. 北京: 中国协和医科大学出版社, 2018: 186.
|
|
|
| [39] |
Shen K L, Wang T Y. Interpretation of Clinical Pathway-Pediatric Internal Medicine Volume. Beijing: Peking Union Medical College Press, 2018: 186.
|
|
|
| [40] |
Hayden F G, Mills S E, Johns M E . Human tolerance and histopathologic effects of long-term administration of intranasal interferon-alpha 2. J Infect Dis, 1983,148(5):914-921.
|
|
|
| [41] |
国琴, 李思思 . 重组人干扰素 α-1b 喷雾剂治疗儿童疱疹性咽峡炎疗效观察. 儿科药学杂志, 2019,25(2):31-33.
|
|
|
| [41] |
Guo Q, Li S S . Observation of curative effect of recombinant human interferon α-1b spray on children with herpetic angina. Journal of Pediatric Pharmacy, 2019,25(2):31-33.
|
|
|
| [42] |
中华人民共和国国家卫生健康委员会. 新型冠状病毒感染的肺炎诊疗方案(试行第六版). 2020:7. [2020-03-02] https://xw.qq.com/cmsid/20200219A0H8TG00.
|
|
|
| [42] |
National Health Committee of the People’s Republic of China. Diagnosis and treatment of pneumonitis with new coronavirus infection,6th ed. 2020:7. [2020-03-02] https://xw.qq.com/cmsid/20200219A0H8TG00.
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
